AFTX-201 uses a proprietary capsid to deliver a human BAG3 transgene, aiming to restore cardiac function with lower doses than conventional gene therapies.

AFTX-201 is designed using Affinia's proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than doses of gene therapies using conventional capsids WALTHAM, ...

A new study published in the journal of Frontiers in Cardiovascular Medicine revealed that Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) were associated with improved left ...

Alnylam Pharmaceuticals recently received a positive reimbursement recommendation in Canada for its RNAi therapy AMVUTTRA in transthyretin-mediated amyloid cardiomyopathy, backed by Phase 3 HELIOS-B ...

Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, ...

Breathlessness or chest pain doesn’t always indicate blocked arteries. Doctors warn these symptoms may signal Hypertrophic ...

Please provide your email address to receive an email when new articles are posted on . Genetic risk for dilated cardiomyopathy was tied to elevated risk for secondary cardiomyopathies related to ...

Intellia said the FDA removed the clinical hold on application for the Phase 3 clinical trial of nexiguran ziclumeran. The study is a randomized, double-blind, placebo-controlled trial evaluating the ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Background A 56-year-old man with normal cardiac function received treatment with interferon α-2b for malignant melanoma. Eight months after the initiation of therapy he developed fatigue and dyspnea ...